Evaxion A/S EVAX
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -38.57%
- 1 year
- -49.13%
- Open
- 3.11
- Prev close
- 3.08
- Mkt cap
- 26.43M
- Vol
- 46.20K
- Avg vol
- 233.92K
- EPS
- -1.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.89
- High
- 3.16
- Forward P/E
- -0.72
- Beta
- -0.23
- Short ratio
- 0.75
- Inst. own
- 9.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.95
- 200-d avg
- 2.95
- 1y target
- 11.56
News
2 days ago globenewswire.com
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, is proud…
2 days ago seekingalpha.com
Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript
Evaxion A/S (EVAX) Discusses EVX-01 Phase II Clinical and Immune Data in Advanced Melanoma Transcript
5 days ago defenseworld.net
Evaxion A/S (NASDAQ:EVAX) Shares Break Below 200 Day Moving Average – What’s Next?
Evaxion A/S - Sponsored ADR (NASDAQ: EVAX - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $3.55 and…
1 week ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 29.7% to $0.42 during Friday's pre-market session. The company's market cap stands at $63.6 million. Electra Therapeutics (NASDAQ:ETRA)…
-
1 week ago benzinga.com
Evaxion Reports All Patients Maintained Clinical Response With No Tumor Progression Through Year Three Of EVX-01 Monotherapy In Advanced Melanoma Phase 2 Trial, 89% Of Vaccine Neoantigens Triggered T-Cell Responses
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in…
1 week ago globenewswire.com
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 23, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
1 week ago globenewswire.com
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform,…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 27.9% to $2.79 during Friday's pre-market session. The company's market cap stands at $5.2 million. Picard Medical (AMEX:PMI) stock…
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Mobile-health Network (NASDAQ:MNDR) shares increased by 141.2% to $2.05 during Monday's pre-market session. The market value of their outstanding shares is at $1.0 million. DataMEDS AI…
1 month ago globenewswire.com
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will…
1 month ago defenseworld.net
Analyzing Nektar Therapeutics (NASDAQ:NKTR) & Evaxion A/S (NASDAQ:EVAX)
Evaxion A/S (NASDAQ: EVAX - Get Free Report) and Nektar Therapeutics (NASDAQ: NKTR - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
1 month ago globenewswire.com
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies The unique…
2 months ago seekingalpha.com
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript
On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For…
-
2 months ago benzinga.com
Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of…
2 months ago globenewswire.com
Evaxion announces business update and second quarter 2026 financial results
COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides…
2 months ago benzinga.com
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings…
-
2 months ago benzinga.com
Evaxion Expands Pipeline Of Cancer Vaccine Programs With EVX-05 Against Deadly Brain Cancer Glioblastoma
EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™…
2 months ago globenewswire.com
Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program
COPENHAGEN, Denmark, August 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, expands it…
2 months ago globenewswire.com
Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026
COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a…
-
3 months ago benzinga.com
Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune responseData will also offer insight into…
3 months ago globenewswire.com
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present…
-
3 months ago benzinga.com
Reported Sunday, Evaxion Presents New Preclinical Data Showing Multi-Component EVX-V1 Vaccine Pairs AI-Discovered Antigens With AI-Optimized Antigens To Target CMV From Multiple Angles
The new data demonstrates the potential to improve control of acute infection, latency, and viral reactivation, further supporting the concept behind EVX-V1EVX-V1 is a next-generation,…
3 months ago globenewswire.com
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
COPENHAGEN, Denmark, July 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data…
-
4 months ago benzinga.com
Evaxion To Present New Preclinical Data For Vaccine Candidate EVX-V1 In Poster Session At IHW 2026
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidatePoster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking…
4 months ago globenewswire.com
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new…
4 months ago globenewswire.com
Evaxion receives Prix Galien UK Award for Best digital health solution
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has been awarded…
-
4 months ago benzinga.com
Evaxion Says AI-Immunology-Developed EVX-04 Shows Immune Activation And Targeted Cell-Killing In Preclinical Acute Myeloid Leukemia Data
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activationThe vaccine antigens drive specific immune responses across different human immune profiles and…
4 months ago globenewswire.com
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
COPENHAGEN, Denmark, June 11, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new…
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
5 months ago benzinga.com
Evaxion To Present Preclinical EVX-04 AML Vaccine Data At EHA 2026, Advancing Toward Planned Clinical Trial Submission In 2H 2026
Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio…
5 months ago globenewswire.com
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will announce the…
5 months ago seekingalpha.com
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
Evaxion A/S (EVAX) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Evaxion Biotech Q1 EPS $(0.01) Beats $(0.23) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.23) by 95.65 percent. This is unchanged from the same period last year.
5 months ago globenewswire.com
Evaxion announces business update and first quarter 2026 financial results
COPENHAGEN, Denmark, May 7, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business…
-
6 months ago benzinga.com
Evaxion Promotes Chief Scientific Officer Birgitte Rono To COO
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, that Birgitte Rønø, its Chief Scientific Officer (CSO),…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
-
6 months ago benzinga.com
Evaxion's Announces Its Data Demonstrating AI-Immunology Traces, Selects Therapeutically Relevant Vaccine Targets; 88% Vaccine Targets Trigger Tumor-Specific Immune Response
Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating that AI-Immunology™…
-
6 months ago benzinga.com
Evaxion Showcases AI-Immunology Platform's Potential To Develop Glioblastoma Vaccines Using Novel Tumor Targets At AACR
Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastomaUniquely, the platform…
-
6 months ago benzinga.com
Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01
EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in…
-
7 months ago benzinga.com
Lake Street Maintains Buy on Evaxion, Lowers Price Target to $9
Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and lowers the price target from $11 to $9.
-
7 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Buy and maintains $16 price target.
-
8 months ago benzinga.com
Evaxion Biotech Q4 EPS $(0.02) Beats $(0.30) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.30) by 93.27 percent. This is a 90.48 percent increase over losses of…
8 months ago benzinga.com
Evaxion Biotech's Earnings: A Preview
Evaxion Biotech's Earnings: A Preview
10 months ago benzinga.com
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evaxion and no change to its cash runway through 2027.
-
10 months ago benzinga.com
Reported Saturday, Evaxion Announces EVX-04 Triggers Specific Immune Responses Across 16 Selected ERV Fragments And Supports Broad Tumor Coverage For Acute Myeloid Leukemia
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigensEVX-04 induces targeted…